Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia

Journal of Clinical Psychiatry

Volumn 66, Issue 9, 2005, Pages 1184-1190

  Evins, A Eden ^a,b   Deckersbach, Thilo ^a,b   Cather, Corinne ^a,b   Freudenreich, Oliver ^a   Culhane, Melissa A ^a   Henderson, David C ^a,b   Green, Michael F ^c   Schoenfeld, David A ^b   Rigotti, Nancy A ^a,b   Goff, Donald C ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE;

ABSTINENCE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; LEARNING; MALE; MEMORY; MOTOR ACTIVITY; NONHUMAN; PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SMOKING CESSATION; TOBACCO;

EID: 26644450242     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0915     Document Type: Article

References (69)

1. de Leon J, Dadvand M, Canuso C, et al. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry 1995; 152: 453-455
2. de Leon J, Tracy J, McCann E, et al. Schizophrenia and tobacco smoking: a replication study in another US psychiatric hospital. Schizophr Res 2002;56:55-65
3. Annual smoking-attributable mortality, years of potential life lost, and economic costs: United States, 1995-1999. MMWR Morb Mortal Wkly Rep 2002;51:300-303
4. Evins AE, Mays VK, Rigotti NA, et al. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 2001;3:397-403
5. Chou KR, Chen R, Lee JF, et al. The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int J Nurs Stud 2004;41:321-330
6. Evins AE, Tisdale T. Bupropion and smoking cessation [letter]. Am J Psychiatry 1999;156:798-799
7. Addington J, el-Guebaly N, Campbell W, et al. Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry 1998;155: 974-976
8. Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 1997;23:247-254
9. George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002;52:53-61
10. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000;157:1835-1842
11. Williams JM, Ziedonis D. Addressing tobacco among individuals with a mental illness or an addiction. Addict Behav 2004;29: 1067-1083
12. Thorndike AN, Stafford RS, Rigotti NA. US physicians' treatment of smoking in outpatients with psychiatric diagnoses. Nicotine Tob Res 2001;3:85-91
13. Levin ED, Conners CK, Sparrow E, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 1996;123:55-63
14. Levin ED, Conners CK, Silva D, et al. Transdermal nicotine effects on attention. Psychopharmacology (Berl) 1998;140:135-141
15. Bates T, Mangan G, Stough C, et al. Smoking, processing speed and attention in a choice reaction time task. Psychopharmacology (Berl) 1995;120:209-212
16. Le Houezec J, Halliday R, Benowitz NL, et al. A low dose of subcutaneous nicotine improves information processing in nonsmokers. Psychopharmacology (Berl) 1994;114:628-634
17. Gilbert DG, Estes SL, Welser R. Does noise stress modulate effects of smoking/nicotine? mood, vigilance, and EEG responses. Psychopharmacology (Berl) 1997;129:382-389
18. Ernst M, Heishman SJ, Spurgeon L, et al. Smoking history and nicotine effects on cognitive performance. Neuropsychopharmacology 2001;25: 313-319
19. Warburton DM, Rusted JM, Fowler J. A comparison of the attentional and consolidation hypotheses for the facilitation of memory by nicotine. Psychopharmacology (Berl) 1992;108:443-447
20. Rusted J, Graupner L, Warburton D. Effects of post-trial administration of nicotine on human memory: evaluating the conditions for improving memory. Psychopharmacology (Berl) 1995;119:405-413
21. Rusted JM, Graupner L, Tennant A, et al. Effortful processing is a requirement for nicotine-induced improvements in memory. Psychopharmacology (Berl) 1998;138:362-368
22. Levin ED, Briggs SJ, Christopher NC, et al. Persistence of chronic nicotine-induced cognitive facilitation. Behav Neural Biol 1992;58: 152-158
23. Levin ED, Christopher NC, Briggs SJ. Chronic nicotinic agonist and antagonist effects on T-maze alternation. Physiol Behav 1997;61:863-866
24. Foulds J, Stapleton J, Swettenham J, et al. Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers. Psychopharmacology (Berl) 1996;127:31-38
25. Perkins KA, Grobe JE, Fonte C, et al. Chronic and acute tolerance to subjective, behavioral and cardiovascular effects of nicotine in humans. J Pharmacol Exp Ther 1994;270:628-638
26. Hatsukami D, Fletcher L, Morgan S, et al. The effects of varying cigarette deprivation duration on cognitive and performance tasks. J Subst Abuse 1989;1:407-416
27. Keenan RM, Hatsukami DK, Anton DJ. The effects of short-term smokeless tobacco deprivation on performance. Psychopharmacology (Berl) 1989;98:126-130
28. Zack M, Belsito L, Scher R, et al. Effects of abstinence and smoking on information processing in adolescent smokers. Psychopharmacology (Berl) 2001;153:249-257
29. Hirshman E, Rhodes DK, Zinser M, et al. The effect of tobacco abstinence on recognition memory, digit span recall, and attentional vigilance. Exp Clin Psychopharmacol 2004;12:76-83
30. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 1998;155:1490-1501
31. Levin ED, Wilson W, Rose JE, et al. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996;15:429-436
32. Depatie L, O'Driscoll GA, Holahan AL, et al. Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology 2002;27:1056-1070
33. Harris JG, Kongs S, Allensworth D, et al. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 2004;29:1378-1385
34. Smith RC, Singh A, Infante M, et al. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2002;27:479-497
35. Myers CS, Robles O, Kakoyannis AN, et al. Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology (Berl) 2004; 174:334-340
36. Olincy A, Johnson LL, Ross RG. Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry Res 2003;117:223-236
37. Adler LE, Hoffer LD, Wiser A, et al. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993;150:1856-1861
38. Adler LE, Hoffer LJ, Griffith J, et al. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 1992;32:607-616
39. Levin ED, Rezvani AH. Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol 2000;393:141-146
40. George TP, Vessicchio JC, Termine A, et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 2002;26:75-85
41. Weiner E, Ball MP, Summerfelt A, et al. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry 2001;158:635-637
42. Dalack GW, Meador-Woodruff JH. Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophr Res 1996;22:133-141
43. Dalack GW, Becks L, Hill E, et al. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 1999;21:195-202
44. Smith CM, Pristach CA, Cartagena M. Obligatory cessation of smoking by psychiatric inpatients. Psychiatr Serv 1999;50:91-94
45. Yang YK, Nelson L, Kamaraju L, et al. Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. Neuropsychopharmacology 2002;27:684-686
46. Silver H, Shlomo N, Hiemke C, et al. Schizophrenic patients who smoke have a faster finger tapping rate than nonsmokers. Eur Neuropsychopharmacol 2002;12:141-144
47. Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 2005;25:218-225
48. Gobbi G, Slater S, Boucher N, et al. Neurochemical and psychotropic effects of bupropion in healthy male subjects. J Clin Psychopharmacol 2003;23:233-239
49. Wilens TE, Prince JB, Spencer T, et al. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biol Psychiatry 2003;54:9-16
50. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158:282-288
51. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996;35:1314-1321
52. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:649-657
53. Becker RE, Dufresne RL. Perceptual changes with bupropion, a novel antidepressant. Am J Psychiatry 1982;139:1200-1201
54. Conners CK. The computerized continuous performance test. Psychopharmacol Bull 1985;21:891-892
55. Delis DC, Kramer JH, Kaplan E, et al. The California Verbal Learning Test-Research Edition. New York, NY: Psychological Corporation; 1987
56. Boll TJ. The Halstead-Reitan Neuropsychological Battery. In: Filskov SB, Boll TJ, eds. Handbook of Clinical Neuropsychology. New York, NY: Wiley-Interscience; 1981:577-607
57. Perlstein WM, Carter CS, Barch DM, et al. The Stroop task and attention deficits in schizophrenia: a critical evaluation of card and single-trial Stroop methodologies. Neuropsychology 1998;12:414-425
58. Wechsler D. Wechsler Adult Intelligence Scale, Third Edition (WAIS-III). San Antonio, TX: Psychological Corporation; 1997
59. Andreasen N. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Iowa: University of Iowa; 1983
60. Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand Suppl 1986;326:1-37
61. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
62. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
63. Lindenmayer JP, Bernstein-Hyman R, Grochowski S, et al. Psychopathology of schizophrenia: initial validation of a 5-factor model. Psychopathology 1995;28:22-31
64. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
65. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
66. Clyde DJ. SAFTEE: data system for side effect assessment scale. Psychopharmacol Bull 1986;22:287
67. National Report on Human Exposure to Environmental Chemicals. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Environmental Health; 2001
68. Levin ED. Nicotinic receptor subtypes and cognitive function. J Neurobiol 2002;53:633-640
69. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667